2019 Aug 30;7(18):2976-2978. doi: 10.3889/oamjms.2019.763. 10.1016/S0959-8049(01)00050-8. The existence of heterogeneity was tested using the Chi square statistics.

We performed a meta- analysis of adverse effects on randomized controlled trials comparing liposomal formulation and conventional anthracyclines on different tumors.

A phase II randomized controlled study of pegylated liposomal doxorubicin and carboplatin vs. gemcitabine and carboplatin for platinum-sensitive recurrent ovarian cancer (GOTIC003/intergroup study) Int J Clin Oncol. The remaining two trials used the WHO criteria for toxicity and one trial used South West Oncology Group (SWOG) toxicity scoring system.

The primary cancer treated was metastatic breast cancer in four trials, multiple myeloma in two trials, AIDS related Kaposi sarcoma in two trials and metastatic soft tissue sarcoma in one trial. Unable to load your delegates due to an error Primary disease sites were well matched. You can also search for this author in The differences on the toxicity grading of the variables were essentially unremarkable among the criteria [The primary end points were the adverse effects: cardiac toxicity with congestive cardiac failure and significant reduction in the left ventricular ejection fraction (LVEF) were entered in separate arms. Randomised phase II trial of pegylated liposomal doxorubicin (DOXIL/CAELYX) versus doxorubicin in the treatment of advanced or metastatic soft tissue sarcoma: a study by the EORTC Soft Tissue and Bone Sarcoma Group. CAELYX/DOXIL, pegylated liposomal doxorubicin, has shown antitumour activity and reduced toxicity compared with standard doxorubicin in other tumour types.

We eliminated studies if the data were not available for a particular variable.Nine randomized controlled trials that enrolled a total of 2220 patients were selected for the meta-analysis (Table Five trials used pegylated liposomal doxorubicin.

The incidence of nausea and vomiting was less with the liposomal arm with an odd ratio of 0.79 (CI; 0.66–0.96).This meta-analysis included nine randomized controlled trials comparing liposomal and conventional anthracyclines.The incidence of hematological toxicity of all grades was lower with liposomal anthracyclines. To compare the tolerability, efficacy, and safety profiles of pegylated liposomal doxorubicin in combination with carboplatin (PLD–Carbo) with those of gemcitabine–carboplatin (Gem–Carbo) for the treatment of patients with platinum-sensitive recurrent ovarian cancer (PSROC) by reviewing the published literature. The liposomes generally exit the circulation in tissues and organs lined with cells that are not tightly joined (fenestrated) or areas where capillaries are disrupted by inflammation or tumor growth. CAELYX was significantly less myelosuppressive, only 3 (6%) patients had grade 3 and 4 neutropenia, versus 33 (77%) on doxorubicin; febrile neutropenia occurred in 7 (16%) patients given doxorubicin, but only 1 (2%) given CAELYX. We performed a meta-analysis from nine randomized controlled trials of various tumors comparing the outcome and the adverse effects of conventional anthracyclines and liposome encapsulated or pegylated liposomal anthracyclines.

For those variables with high heterogeneity(p<0.05 for I-squared analysis), the data were analyzed using the random effect model. Epub 2006 Aug 7.Judson I, Verweij J, Gelderblom H, Hartmann JT, Schöffski P, Blay JY, Kerst JM, Sufliarsky J, Whelan J, Hohenberger P, Krarup-Hansen A, Alcindor T, Marreaud S, Litière S, Hermans C, Fisher C, Hogendoorn PC, dei Tos AP, van der Graaf WT; European Organisation and Treatment of Cancer Soft Tissue and Bone Sarcoma Group.Lancet Oncol. To minimize the bias, we used random effects models for the studies with high heterogeneity, as recommended and performed by many statisticians and meta-analysis publications [Liposomal doxorubicin and pegylated liposomal doxorubicin demonstrated favorable toxicity profiles with better cardiac safety and less myelosuppression, alopecia, nausea and vomiting compared with the conventional antracyclines.

BL, GL and GW participated in reference preparation and formatting.

COVID-19 is an emerging, rapidly evolving situation.

2014 Apr;15(4):415-23. doi: 10.1016/S1470-2045(14)70063-4.

Epub 2020 Feb 1.Molecules. To our knowledge this is the first meta-analysis comparing the safety of the conventional anthracyclines and the liposome encapsulated anthracyclines.We used a broad search strategy with special emphasis on randomized controlled trials. The information of the different grades of hematology toxicity was not available in two of the trials. In this prospective randomised trial, 94 eligible patients with advanced soft-tissue sarcoma (STS) were treated, 50 with CAELYX (50 mg/m(2) by a 1 h intravenous (i.v.) The searches were combined with the key word search “randomized controlled trials”.

In conclusion, CAELYX has equivalent activity to doxorubicin in STS with an improved toxicity profile and should be considered for further investigation in combination with other agents such as ifosfamide.

Our aim is to evaluate the adverse effects and quantify the relative safety profile of the liposomal and conventional anthracyclines through meta-analysis of the published randomized trials.We conducted a broad search strategy of major electronic databases.

2020 May;15(3):385-396. doi: 10.1016/j.ajps.2019.04.007. 2019 Oct;24(10):1284-1291. doi: 10.1007/s10147-019-01471-5. There are no variations among the two groups within the studies. The overall ORs were calculated from the pooled data.